Sponsor:
Yale University
Code:
NCT04711915
Conditions
Major Depressive Disorder
Depression
Eligibility Criteria
Sex: All
Age: 21 - 65
Healthy Volunteers: Accepted
Interventions
0.1 mg/kg Dimethyltryptamine (DMT)
0.3 mg/kg Dimethyltryptamine (DMT)
Brief summary:
Conditions
Major Depressive Disorder
Depression
Study ID
NCT04711915
Start date
Mar 17, 2021
Status verified date
Nov, 2026
Completion date
Dec 1, 2030
Anticipated
Primary completion date
Jul 1, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 21 - 65
Healthy Volunteers: Accepted
Enrollment
10 participants
Anticipated
Allocation
Non randomized
Intervention Model
Crossover
Primary purpose
Other
Arms
active comparator: 0.1 mg/kg DMT
active comparator: 0.3 mg/kg DMT
Interventions
0.1 mg/kg Dimethyltryptamine (DMT)
0.3 mg/kg Dimethyltryptamine (DMT)
Primary outcome measure
Central contacts
Locations
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
Recruiting
West Haven, Connecticut, United States, 06516
Contacts
Schizophrenia Research Clinic
203-932-5711Principal Investigator:
Deepak C D'Souza, MD
Sponsor
Yale University
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Yale University on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.